Methods of diagnosing sepsis by measuring HMG1
View Patent ↗There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
1. A method for diagnosing a sepsis condition in a mammalian subject suspected of having sepsis, comprising
measuring the concentration of high mobility group 1 (HMG1) in a test sample from the subject wherein the test sample is a blood sample, and
comparing that concentration to a concentration of a standard for HMG1 representative of a normal range of HMG1 in a sample from the same species as said subject,
wherein a concentration of HMG1 in the test sample higher than the standard indicates a diagnosis of a sepsis condition.
2. The method of claim 1 , wherein the mammalian subject is human.
3. The method of claim 1 , wherein the concentration of HMG1 is measured by contacting said sample with an antibody that binds an HMG1 protein.
4. A method for diagnosing a sepsis condition in a mammalian subject suspected of having sepsis, comprising
measuring the concentration of high mobility group 1 (HMG1) in a test sample from the subject wherein the test sample is a serum sample, and
comparing that concentration to a concentration of a standard for HMG1 representative of a normal range of HMG 1 in a sample from the same species as said subject,
wherein a concentration of HMG1 in the test sample higher than the standard indicates a diagnosis of a sepsis condition.
5. The method of claim 4 , wherein the mammalian subject is human.
6. The method of claim 4 , wherein the concentration of HMG1 is measured by contacting said sample with an antibody that binds an HMG1 protein.